Sabby Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Sabby Management’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-69,103	Closed	-$22K	–	156
2022 Q1	$22K	Sell	69,103 -315,494	-82%	-$337K	﹤0.01%	138
2021 Q4	$885K	Buy	384,597 +18,137	+5%	+$53.5K	0.13%	85
2021 Q3	$847K	Sell	366,460 -33,620	-8%	-$127K	0.11%	94
2021 Q2	$2.19M	Sell	400,080 -78,861	-16%	-$425K	0.31%	53
2021 Q1	$2.51M	Buy	+478,941	New	+$2.62M	0.49%	39
2015 Q1	–	Sell	-18,858	Closed	-$108K	–	334
2014 Q4	$108K	Sell	18,858 -25,195	-57%	-$197K	﹤0.01%	219
2014 Q3	$404K	Buy	44,053 +28,745	+188%	+$263K	0.02%	194
2014 Q2	$147K	Sell	15,308 -76,000	-83%	-$888K	0.01%	234
2014 Q1	$1.24M	Buy	+91,308	New	+$1.49M	0.07%	129

Other funds holding STAB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sabby Management's STAB Position: Q2 2022 in Review

Sabby Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2022, closing a stake of 69,103 shares — an estimated $22K sold.

Sabby Management first reported a position in STAB in Q1 2014 and held it in 9 quarters. The position peaked at $2.51M in Q1 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q2 2022.

Sabby Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Sabby Management sold 69,103 Statera Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $22K.
Sabby Management first reported a position in Statera Biopharma, Inc. Common Stock in Q1 2014 and held it in 9 quarters.
Sabby Management's Statera Biopharma, Inc. Common Stock position peaked at $2.51M in Q1 2021.
35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2022.

Based on Sabby Management's 13F filing for Q2 2022, filed 15 Aug 2022.